This week in therapeutics




Licensing status

Publication and contact information



Sphingosine 1-phosphate receptor 3 (S1PR3; S1P3; EDG3)

Cell culture and mouse studies suggest S1PR3 agonists could help treat wound healing. In human umbilical vein endothelial cells, the S1PR1 (S1P1; EDG1) and S1PR3 agonist Gilenya fingolimod increased the secretion of proregenerative cytokines compared with no treatment. In mice surgically implanted with subdermal, thin polymer films, embedding Gilenya in the polymer increased microvascular growth and the recruitment of anti-inflammatory monocytes around the implant compared with what was seen using control polymer films. In a mouse model of muscle ischemia, Gilenya-coated, thin polymer films inserted next to the damaged muscle tissue increased recruitment of anti-inflammatory monocytes to ischemic vessels and arteriogenesis compared with uncoated films. Next steps could include optimizing S1PR3 agonists and testing them in preclinical models of wound healing.
Mitsubishi Tanabe Pharma Corp. and Novartis AG market Gilenya to treat multiple sclerosis (MS).

SciBX 6(35); doi:10.1038/scibx.2013.961
Published online Sept. 12, 2013

Patent and licensing information unavailable

Awojoodu, A.O. et al. Proc. Natl. Acad. Sci. USA; published online Aug. 5, 2013;
Contact: Edward Botchwey, Georgia Institute of Technology, Atlanta, Ga.